Patients starting or currently receiving ocrelizumab, ublituximab, rituximab
You may not be if
Adults unable or unwilling to consent
Patients younger than 18 years of age
Pregnant women
Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine
Moderate or severe renal impairment (creatinine clearance or 11-31 mL/min or worse)
Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2/proton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions)
